DeepMed Research

Prazosin

Generic Name: Prazosin

Brand Names: Minipress, Minizide

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₁N_₅O_₄

CAS Number: 19216-56-9

Unique Ingredient Identifier: XM03YJ541D

Background: Prazosin is a drug used to treat hypertension. Prazosin is marketed by Pfizer and was initially approved by the FDA in 1988. It belongs to the class of drugs known as alpha-1 antagonists.

Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTSD) and associated nightmares.

Indication: This drug is indicated for the treatment of hypertension (high blood pressure). Prazosin can be given alone or given with other blood pressure-lowering drugs, including diuretics or beta-adrenergic blocking agents .

Prazosin does not negatively impact lung function, and therefore may be used to manage hypertension in patients who are asthmatic or patients with chronic obstructive lung disease (COPD).

Associated Conditions: Agitation, Benign Prostatic Hyperplasia (BPH), Hypertension, Raynaud's Phenomenon, Disturbed sleep/nightmares

Clinical Trials

Brain Blood Vessel Responses to Changes in Blood Flow: Younger Cohort

Phase 2

Not yet recruiting

Conditions: Magnetic Resonance Imaging
Cerebrovascular Circulation

Interventions: Device: MRI
Drug: Prazosin
Drug: Placebo

First Posted Date: 2024-10-08

Last Posted Date: 2025-04-24

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 36

Registration Number: NCT06629090

Locations: 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States

Brain Blood Vessel Responses to Changes in Blood Flow

Phase 2

Not yet recruiting

Conditions: Magnetic Resonance Imaging
Cerebrovascular Circulation

Interventions: Device: MRI
Drug: Prazosin
Drug: Placebo

First Posted Date: 2024-10-08

Last Posted Date: 2025-04-24

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 36

Registration Number: NCT06629077

Locations: 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States

A Comparative Study of Using Scorpion Antivenom Versus Scorpion Antivenom and Prazosin

Phase 4

Recruiting

Conditions: Morality

Interventions: Drug: Prazosin Oral Tablet

First Posted Date: 2024-03-01

Last Posted Date: 2024-03-01

Lead Sponsor: Sohag University

Target Recruit Count: 80

Registration Number: NCT06287905

Locations: 🇪🇬
Meray Medhat Shokry Zaghary, Sohag, Egypt

A Study to Assess the Pharmacokinetic Profile of Prazosin and Cyproheptadine

Phase 1

Completed

Conditions: Alcohol Use Disorder

Interventions: Drug: KT110
Drug: Prazosin + cyproheptadine

First Posted Date: 2023-11-27

Last Posted Date: 2025-03-13

Lead Sponsor: Kinnov Therapeutics

Target Recruit Count: 12

Registration Number: NCT06147622

Locations: 🇫🇷
Eurofins Optimed, Gières, France

A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline

Phase 1

Terminated

Conditions: Post-traumatic Stress Disorder (PTSD)

Interventions: Drug: Propranolol
Drug: Prazosin

First Posted Date: 2022-01-13

Last Posted Date: 2024-01-23

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 34

Registration Number: NCT05189977

Locations: 🇺🇸
For additional information regarding sites (California, Texas, New Jersey, Minnesota), Princeton, New Jersey, United States

Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride Capsules

Phase 1

Completed

Conditions: Hypertension
Heart Failure

Interventions: Drug: Prazosin HCl 2mg
Drug: Prazosin HCl 1 mg
Drug: Prazosin HCl 5 mg

First Posted Date: 2021-07-19

Last Posted Date: 2024-07-12

Lead Sponsor: Pfizer

Target Recruit Count: 72

Registration Number: NCT04967443

Locations: 🇺🇸
Clinical Trials of Texas, LLC, San Antonio, Texas, United States

Prazosin for Alcohol Use Disorder with Withdrawal Symptoms

Phase 2

Recruiting

Conditions: Alcohol Withdrawal

Interventions: Drug: Prazosin
Behavioral: 12-Step Facilitation with Relapse Prevention and Contingency Management

First Posted Date: 2021-03-11

Last Posted Date: 2025-02-21

Lead Sponsor: Yale University

Target Recruit Count: 150

Registration Number: NCT04793685

Locations: 🇺🇸
The Yale Stress Center: Yale University, New Haven, Connecticut, United States

Reducing Cannabis Overuse With Prazosin

Phase 4

Recruiting

Conditions: Cannabis Dependence
Posttraumatic Stress Disorder
Cannabis Use Disorder

Interventions: Drug: Prazosin Hydrochloride

First Posted Date: 2021-01-22

Last Posted Date: 2023-12-29

Lead Sponsor: VA Puget Sound Health Care System

Target Recruit Count: 20

Registration Number: NCT04721353

Locations: 🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States

Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)

Phase 2

Terminated

Conditions: COVID-19

Interventions: Other: Standard of care
Drug: Prazosin

First Posted Date: 2020-04-28

Last Posted Date: 2023-04-10

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 5

Registration Number: NCT04365257

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

Administration of Prazosin to Prevent PTSD in Adult Women After Sexual Assault

Phase 4

Conditions: Posttraumatic Stress Disorder

Interventions: Drug: Placebos
Drug: Prazosin

First Posted Date: 2019-06-25

Last Posted Date: 2020-09-30

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 40

Registration Number: NCT03997864

Locations: 🇺🇸
University of Colorado, Aurora, Colorado, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy